# Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

> **NCT06548542** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 540 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Lutikizumab
- **DRUG:** Trosunilimab
- **DRUG:** Risankizumab
- **DRUG:** Trosunilimab
- **DRUG:** ABBV-8736

## Key facts

- **NCT ID:** NCT06548542
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-04
- **Primary completion:** 2027-12
- **Final completion:** 2028-08
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06548542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06548542, "Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06548542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*